Global pharmaceutical regulation: The challenge of integration for developing states

Globalization and Health

Volumn 12, Issue 1, 2016, Pages

  Pezzola, Anthony ^a   Sweet, Cassandra M ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Access to medicine; Developing countries; Pharmaceuticals; Regulation; World Health Organization

Indexed keywords

ACCESSIBILITY; DEVELOPING WORLD; DRUG; MEDICINE; PHARMACEUTICAL INDUSTRY; REGULATORY FRAMEWORK; WORLD HEALTH ORGANIZATION;

ARTICLE; BUILDING; CHINA; CONTROLLED STUDY; DEVELOPING COUNTRY; DIFFUSION; DRUG MARKETING; EUROPEAN UNION; HUMAN; INDIA; MONITORING; ORGANIZATION AND MANAGEMENT; PATENT; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; UNITED STATES; WORLD HEALTH ORGANIZATION; DRUG CONTROL; HEALTH CARE DELIVERY; HEALTH CARE POLICY; INTERNATIONAL COOPERATION; LEGISLATION AND JURISPRUDENCE; PROCEDURES; TRENDS;

DEVELOPING COUNTRIES; DRUG AND NARCOTIC CONTROL; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONALITY; WORLD HEALTH ORGANIZATION;

EID: 85006759601     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/s12992-016-0208-2     Document Type: Article

References (59)

1. Sell S. Intellectua1 property protection and antirust in the developing world: Crisis, coercion and choice. Int Organ. 1995;49:315-50.
2. Sell S. Private power, public law: the globalization of intellectual property rights. Cambridge, UK: Cambridge University Press; 2003.
3. Jawara F, Kwa A. Behind the scenes at the WTO. London: Zed Books; 2003.
4. Haakonsson SJ, Richey LA. TRIPs and public health: the Doha Declaration and Africa. Development Policy Review. 2007;25:71-90.
5. Matthews D. WTO decision on implemenationa of paragraph 6 on the DOHA declaration on the TRIPS agreement and public health. J Int Econ Law. 2004;7:73-107.
6. Fink C, Reichenmiller P. Tightening TRIPS: intellectual property provisions of U.S. free trade agreements. In: Newfarmer R, editor. Trade, Doha, and development: a window into the issues. Washington, D.C: The World Bank; 2006. p. 285-300.
7. Roffe P. Bilateral agreements and a TRIPS-plus world: the Chile-USA Free Trade Agreement. QIAP. 2004; http://www.quno.org/sites/default/files/resources/FTAs-TRIPS-plus-English_0.pdf
8. Shadlen K. International change and national responses: social coalitions and patent politics in Latin American in the 1990s. Prepared in preparation for the Meetings of the Latin American Political Economy Network. 2014; Santiago, Chile
9. Shadlen K. Patent politics: the political economy of intellectual property rights in Latin America. Presented at the annual meeting of the International Studies Association. Montreal, Quebec, Canada 2004
10. Deere C. The implementation game: the TRIPS agreement and the global politics of intellectual property reform in developing countries. Oxford: Oxford University Press; 2009.
11. Abbott FM, Dukes G. Global pharmaceutical policy. London and New York: Edward Elgar; 2009.
12. Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha declaration: a database analysis. PLoS Med. 2012;9:e1001154.
13. Sampat B, Shadlen K. The form and effectiveness of policies to limit secondary pharmaceutical patents in Brazil and India. Annual Meeting of the American Political Science Association. 2013; August 29-September 1
14. Correa CM. Pharmaceutial innovation, incremental patenting and compulsory licensing. South Centre Research Paper. 2011. p. 41.
15. Chorev N. Narrowing the gaps in global disputes: the case of counterfeits in Kenya. Stud Comp Int Dev. 2015;50:157-86.
16. Gervais D. The TRIPS agreement: drafting history and analysis. London: Sweet and Maxwell 2008.
17. Correa CM. Intellectual property rights, the WTO and developing countries: the TRIPS agreement and policy options. London: Zed Books; 2000.
18. Sweet C. Comparative health systems: emerging generics regulations in Latin America. Presented at the Midwest Political Science Association, Currently under review. 2014.
19. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 Low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33:689-703. doi: 10.2165/11536390-000000000-00000.
20. Ngwainmbi EK. Healthcare management strategy, communication and development challenges and solutions in developing countries. Lanham, Maryland. 2014; Lexington Books
21. Tobar F, Drake I, Martich E. Alternativas para la adopción de políticas centradas en el acceso a medicamentos. Revista Panamericana de Salud Pública. 2012;32:457-63.
22. Kaplan W, Ritz LS, Vitello M, Wirtz V. Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000-2010. Health Policy. 2012;106:211-24.
23. Jakovljevic M, Lazarevic M, Milovanovic O, Kanjevac T. The new and old Europe: east-west split in pharmaceutical spending. Front Pharmacol. 2016;7:18.
24. Jordana J. The institutional development of Latin American regulatory state. In: Levi-Faur D, editor. Handbook on the politics of regulation. Cheltenham: Edward Elgar; 2012. p. 156-70.
25. Weyland K. Bounded rationality and policy diffusion: social sector reform in Latin America. Princeton University Press: Princeton; 2007.
26. Shadlen K. The Mexican exception: patents and innovation policy in a non-conformist and reluctant middle income country. Eur J Dev Res. 2012;24:300-18.
27. Carpenter D. Reputation, Information and Confidence - The Political Economy of Pharmaceutical Regulation. Essay for Farber and O'Connell Public Choice and Public Law Volume. 2010
28. Nunn AS, Fonseca EM, Bastos F, Gruskin S. AIDS treatment in Brazil: impacts and challenges. Health Aff. 2009;28:1103-13.
29. Teixeira PR, Vitoria MA, Barcarolo J. The Brazilian experience in providing universal access to antiretroviral therapy. Economics of AIDS and access to HIV/AIDS care in developing countries. Agence Nationale de Recherches sur le Sida: Issues and Challenges; 2003.
30. Orsi F, Hasenclever L, Fialho B, Tigre P, Coriat B. Intellectual property right, anti-AIDS policy and generic drugs: lessons from the Brazilian Public Health Program. Economics of AIDS and access to HIV/AIDS care in developing countries, issues and challenges. Paris: Agence Nationale de Recherches sur le Sida; 2003.
31. Cassier M, Correa M. Scaling-up and reverse engineering: acquisition of industrial knowledge by copying drugs in Brazil. In: Coriat B, editor. The political economy of HIV/AIDS in developing countries: TRIPS, public health systems and free access. Cheltenham, UK: Edward Elgar; 2008.
32. Possas CA. Compulsory licensing in the real world: the case of ARV drugs in Brazil. In: Coriat B, editor. The political economy of HIV/AIDS in developing countries. Cheltenham, UK: Edward Elgar; 2008.
33. Sweet C. The political economy of pharmaceuticals in Brazil. In: Lofgren H, Williams O, editors. Global pharmaceutical politics and production. London: Palgrave 2013. p. 29-47.
34. Pal SN, Dodoo A, Mantel A, Olsson S. Pharmacovigilance and safety of medicines. In: World Health Organization, editor. The World medicines situation 2011. 3rd ed. Geneva: World Health Organization; 2011.
35. Nolan P. China and the global business revolution. London: Palgrave 2001.
36. Grace C. A briefing paper for DFID: update on china and India and access to medicines. London: DFID Health Resource Centre; 2005.
37. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization; 2009.
38. Quinn KM. Bayesian factor analysis for mixed ordinal and continuous responses. Polit Anal. 2004;12:338-53.
39. Diack A, Seiter A, Hawkins L, Dweik IS. Assessment of governance and corruption in the pharmaceutical sector - lessons learned from low and middle income countries. Washington, DC: Health, Nutrition, and Population Family (HNP) of the World Bank; 2010
40. Anisfeld M, An L, Mbaziira N, Kagoya H. Sagwa. Strengthening the capacity of the Namibia Medicines Regulatory Council in the regulation of antiretroviral medicines and other essential pharmaceuticals in Namibia. Arlington, VA: Management Sciences for Health; 2014.
41. Seiter A. A practical approach to pharmaceutical policy. Washington DC: World Bank; 2010.
42. Al-Essa RK, Al-Rubaie M, Walker S, Salek S. Pharmaceutical regulatory environment: challenges and opportunities in the Gulf region. New York: Springer; 2015.
43. Chee G, Borowitz M, Barraclough A. Private sector health care in Indonesia. Bethesda, MD: Health Systems 20/20 project; 2009.
44. Bank W. Pharmaceuticals: why reform is needed. Indonesia health sector review: policy and discussion notes. Washington, DC: World Bank; 2009.
45. World Bank. Pharmaceuticals: why reform is needed. Indonesia health sector review: policy and discussion notes. Washington, DC: World Bank; 2009.
46. SHOPS. Strengthening health outcomes through the private sector and health systems 20/20: Dominica Health Systems and Private Sector Assessment. Health Systems 20/20 and SHOPS 2012
47. WHO. World medicines situation report 2011. Geneva: World Health Organization; 2011.
48. Ashigbie PG. Pharmaceutical regulation: A twelve country study. Boston University, School of Health (Accessed 10 June 2016) Available from http://apps.who.int/medicinedocs/documents/s18042en/s18042en.pdf. 2010.
49. Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation. A multicountry study Geneva. World Health Organization.: Switzerland 2002.
50. Jakovljevic M, Djordjevic N, Jurisevic M, Jankovic S. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes Res. 2015;15:521-30.
51. Carpenter D, Chattopadhyay J, Moffitt S, Nall C. The complications of controlling agency time discretion: FDA review deadlines and postmarket drug safety. Am J Polit Sci. 2011;56:98-114.
52. DiMaggio PJ, Powell WW. The iron cage revisited: institutional isomorphism and collective rationality in organizational fields. Am Sociol Rev. 1983;48:147-60.
53. Deere-Birkbeck C. Global governance in the context of climate change: the challenges of increasingly complex risk parameters. Int Aff. 2011;85:1173-94.
54. Ginarte J, Park W. Determinants of patent rights: A cross-national study. Research Policy. 1997;26:283-301.
55. Park WG. International patent protection: 1960-2005. Res Policy. 2008;37:761-6.
56. Vukovic M, Gvozdenovic BS, Rankovic M, McCormick BP, Vukovic DD, Gvozdenovic BD, et al. Can Didactic Continuing Education Improve Clinical Decision Making and Reduce Cost of Quality? Evidence From a Case Study. Journal of Continuing Education in the Health Professions. 2015;35:109-18.
57. Jakovljevic M, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res. 2014;14:181-94.
58. Homedes N, López Linares R, Ugalde A. Generic drug policies in Latin America. Health, Nutrition and Population (HNP), Discussion Paper, World Bank. 2005.
59. Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. The Lancet HIV. 2016;3:e361-87.